|
Navidea Biopharmaceuticals Inc (NAVB) |
|
Navidea Biopharmaceuticals Inc
NAVB's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Navidea Biopharmaceuticals Inc 's sales fell
in III. Quarter 2023 from the same quarter a year ago.
In Vitro & In Vivo Diagnostic Substances industry recorded
growth of revenues by 11.11 %
Navidea Biopharmaceuticals Inc net loss decreased from $-6 millions, to $-2 millions in III. Quarter 2023,
• More on NAVB's Growth
|
|
Navidea Biopharmaceuticals Inc realized a net loss in trailing twelve months.
Navidea Biopharmaceuticals Inc realized cash reduction of $ -0 per share in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 97.74.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 6.86.
• More on NAVB's Valuation
|
|
|
|
|
Navidea Biopharmaceuticals Inc realized net loss in trailing twelve months.
Navidea Biopharmaceuticals Inc realized cash outflow of $ -0per share in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 97.74.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 6.86.
• More on NAVB's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com